Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Cushing Syndrome 1Adrenal Hyperplasia, Congenital 1ACTH Syndrome, Ectopic 1

Interventions

pembrolizumab 219Carboplatin 218Specimen Handling 198Cisplatin 188Magnetic Resonance Spectroscopy 168Radiotherapy 152Bevacizumab 142Gemcitabine 135Cyclophosphamide 133Drug Therapy 118Capecitabine 118Paclitaxel 112Oxaliplatin 110Biopsy 107venetoclax 102Nivolumab 101Rituximab 83tislelizumab 81durvalumab 81toripalimab 77Fluorouracil 73Etoposide 72Dexamethasone 70sintilimab 67Radiosurgery 67Docetaxel 67Pemetrexed 65atezolizumab 64Azacitidine 63Injections 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Recruiting × Osilodrostat × Clear all
NCT07104812 2026-02-11

Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)

Mayo Clinic

Phase 2 Recruiting
15 enrolled

ACTH Syndrome, Ectopic, Adrenal Hyperplasia, Congenital, Cushing Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡